Recombinant Human CDKN1B
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Documents del producto
Product specifications
| Category | Proteins and Peptides |
| Host | E.Coli |
| Reactivity | Human |
| Assay Data | Centrifuge the vial before opening, reconstitute in sterile distilled water to a concentration of 0.1-1 mg/ml by gently pipetting 2-3 times, don't vortex. |
| Recommended Dilution | ¥ |
| Isotype | ¥ |
| Clone ID | ¥ |
| Observed MW | 21.7 kDa |
| Expression | 1-198 |
| Purity | Greater than 90% as determined by SDS-PAGE. |
| Size 1 | 50μg |
| Size 2 | 200μg |
| Size 3 | 1mg |
| Form | Lyophilized powder |
| Tested Applications | Western Blot, ELISA |
| Buffer | Lyophilized from a 0.2 μm filtered solution in 10 mM Hepes, 500 mM NaCl with 5% trehalose, pH 7.4. |
| Availability | 3-4 weeks |
| Storage | The lyophilized protein is stable at -20 °C for up to 1 year. After reconstitution, the protein solution is stable at -20 to -80 °C for 3 months or 1 week at 2 to 8 °C under sterile conditions. For extended storage, it is recommended to further dilute in working aliquots, avoid repeated freeze/thaw cycle. |
| UniProt ID | P46527 |
| Alias | AA408329, AI843786, Cdki1b, CDKN 1B, CDKN 4, CDKN1B, CDKN4, CDN1B_HUMAN, Cyclin Dependent Kinase Inhibitor 1B, Cyclin dependent kinase inhibitor p27, Cyclin-dependent kinase inhibitor 1B, Cyclin-dependent kinase inhibitor 1B (p27, Kip1), Cyclin-dependent kinase inhibitor p27 |
| Background | Protein CDKN1B |
| Status | RUO |
| Note | Tag : N-terminal His Tag or N-terminal His-IF2DI Tag, determined during production process |
Related Products
Human CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit
Ver Producto
Mouse CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit
Ver Producto
CDKN1B antibody
CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.
Ver Producto